The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Subcutaneous amivantamab shows fewer IRRs over IV in NSCLC
Balazs Halmos, MD, Montefiore Medical Center, New York, NY, compares rates of administration-related reactions with subcutaneous versus intravenous (IV) amivantamab in non-small cell lung cancer (NSCLC), investigated in the COPERNICUS (NCT06667076) and MARIPOSA (NCT04487080) trials respectively. With the IV formulation, infusion-related reactions (IRRs) were common, happening to 55% of patients, with 5% at grade 3 or higher. In contrast, administration-related reactions to subcutaneous amivantamab were uncommon, with a rate of 3% and 1% at grade 3 or higher. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
